Curcumin co-treatment ameliorates resistance to gefitinib in drug- resistant NCI-H1975 lung cancer cells.

CONCLUSION: Co-treatment of curcumin and gefitinib significantly improves the ability of gefitinib to inhibit cell proliferation, suppress the clonogenic capacity and enhance apoptosis in NCI-H1975 cells, and these effects are possibly mediated via a decrease in phosphorylation of proteins in downstream pathways of the epidermal growth factor receptor. PMID: 31682378 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/31682378?dopt=Abstract

Source: Journal of Traditional Chinese Medicine - May 31, 2017 Category: Complementary Medicine Authors: Jin X, Wang J, Shen H, Ran R, Xu K, Zhang W, Tong X, Feng L Tags: J Tradit Chin Med Source Type: research